Liprolog Junior Kwikpen (Insulin Lispro)

Insulin lispro mimics natural insulin but binds more quickly to insulin receptors. It rapidly stimulates glucose uptake into muscle and fat cells and suppresses liver glucose output, providing fast reduction of blood sugar after meals.

The dose of insulin lispro is individualized. A qualified prescriber determines the amount, timing, and frequency based on the patient’s blood‑glucose readings, carbohydrate intake, and overall treatment plan.

Data on insulin lispro use during pregnancy and lactation are limited. It may be used only when the expected benefit to the mother outweighs any potential risk to the fetus or infant, and under close medical supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Compared with regular (short‑acting) human insulin, insulin lispro has a faster onset of action and a shorter duration, allowing more flexible mealtime dosing and reduced risk of post‑prandial hyperglycemia. Both require careful monitoring for hypoglycemia.

Store the pen at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the pen. If needed, it can remain at controlled room temperature (up to 30 °C) for up to 28 days, but refrigeration is preferred for potency.

The pen is designed for subcutaneous injection. After attaching a new needle, the user primes the pen, selects the prescribed dose, and injects into the abdomen, thigh, or upper arm at a 90° angle, rotating sites with each use.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early symptoms and have rapid‑acting glucose on hand.

Individuals with a known hypersensitivity to insulin lispro or any component of the formulation should avoid its use. Caution is also advised for patients with severe renal or hepatic impairment, and it should not be used without medical supervision in pregnant or lactating women unless deemed necessary.